一、 说明会类型 证券代码：603087 证券简称：甘李药业 公告编号：2024-075 甘李药业股份有限公司 关于召开 2024 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 甘李药业股份有限公司（以下简称"公司"）将于 2024 年 10 月 23 日在上 海证券交易所网站（www.sse.com.cn）披露《2024 年第三季度报告》。为便于广 大投资者更全面深入地了解公司状况，公司决定 2024 年 10 月 28 日上午 9:00- 10:00 举行 2024 年第三季度业绩说明会，对公司的经营业绩、公司战略、现金分 红等具体情况进行充分交流。 三、 说明会出席人员 出席本次年度报告网上业绩说明会的人员：公司董事、总经理都凯先生，独 立董事郑国钧先生，财务负责人、副总经理孙程先生，董事会秘书邹蓉女士等高 级管理人员。 如有特殊情况，参会人员将可能进行调整。 四、 投资者参加方式 1、投资者可在 2024 年 10 月 28 日上午 9:00-10:00，通过互联网登 ...

中信证券股份有限公司关于甘李药业股份有限公司 首次公开发行部分限售股上市流通的核查意见 中信证券股份有限公司（以下简称"中信证券"或"保荐机构"）作为甘李 药业股份有限公司（以下简称"甘李药业"或"公司"）持续督导工作的保荐机 构，根据《证券发行上市保荐业务管理办法》《上海证券交易所股票上市规则》 《上海证券交易所上市公司自律监管指引第 11 号——持续督导》等有关规定， 就甘李药业首次公开发行部分限售股上市流通事项进行了核查，核查情况如下： 一、本次限售股上市类型 公司首次公开发行完成后总股本为 401,100,000 股，其中有限售条件流通股 为 360,900,000 股，无限售条件流通股为 40,200,000 股。 1 公司于 2020 年 7 月 23 日召开 2020 年第二次临时股东大会审议通过《2019 年年度利润分配预案》，公司以利润分配实施前的公司总股本 401,100,000 股为基 数，向全体股东每股派发现金红利 0.5 元（含税），每股派送红股 0.4 股，共计派 发现金红利 200,550,000 元，派送红股 160,440,000 股。上述利润分配方案已实施 完毕，公司总股本 ...

证券代码：603087 证券简称：甘李药业 公告编号：2024-074 本次上市流通的限售股为公司首次公开发行限售股，涉及股东为明华创新技 术投资（香港）有限公司（以下简称"明华创新"）。明华创新本次限售股上市流 通数量为 15,875,800 股，占公司目前总股本的 2.64%。根据公司《首次公开发行股 票招股说明书》及上市公告书，首次公开发行前涉及本次上市流通限售股份持有人 对所持股份自愿锁定的承诺，上述股份锁定期为自公司股票上市之日起 12 个月法 定锁定期届满后继续延长锁定，直至甘忠如书面通知解除延长锁定或出现锁定协 议约定的其他终止锁定的情形方能解锁。 截至本公告披露日，甘忠如已出具解除延长锁定的书面通知，明华创新持有的 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 1 一、本次限售股上市类型 本次股票上市类型为首发股份；股票认购方式为网下，上市股数为 15,875,800 股。 本次股票上市流通总数为 15,875,800 股，均为首发限售股 本次股票上市流通日期为 2024 年 10 月 1 ...

证券代码：603087 证券简称：甘李药业 公告编号：2024-073 甘李药业股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/9/6 | | --- | --- | | 回购方案实施期限 | 2024 年 9 月 5 日~2025 年 9 月 4 日 | | 预计回购金额 | 15,000 万元~30,000 万元 | | 回购用途 | □减少注册资本 | | | √用于员工持股计划或股权激励 | | | □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 累计已回购股数 | 39.69 万股 | | 累计已回购股数占总股本比例 | 0.0660% | | 累计已回购金额 | 万元 1,512.5293 | | 实际回购价格区间 | 37.65 元/股~38.42 元/股 | 二、 回购股份的进展情况 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关 ...

重要内容提示： | 回购方案首次披露日 | 2024/9/6 | | --- | --- | | 回购方案实施期限 | 自董事会审议通过回购方案之日起 个月内 12 | | 预计回购金额 | 万元~30,000 万元 15,000 | | 回购用途 | □减少注册资本 | | | √用于员工持股计划或股权激励 | | | □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 累计已回购股数 | 24.38 万股 | | 累计已回购股数占总股本比例 | 0.04% | | 累计已回购金额 | 932.8884 万元 | | 实际回购价格区间 | 37.85 元/股~38.42 元/股 | 一、 回购股份的基本情况 证券代码：603087 证券简称：甘李药业 公告编号：2024-072 甘李药业股份有限公司 关于以集中竞价交易方式首次回购公司股份的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据《上海证券交易所上市公司自律监管指引第 7 号—回购股份》等相关规 定，现将公司首次回购股份情况公告如下： 甘李 ...

证券代码：603087 证券简称：甘李药业 公告编号：2024-071 甘李药业股份有限公司 | 7 | 中国银行股份有限公司－招商国证生物医药指 | 5,732,300 | 0.95 | | --- | --- | --- | --- | | | 数分级证券投资基金 | | | | 8 | 中国农业银行股份有限公司－中证 交易型 500 | 4,502,528 | 0.75 | | | 开放式指数证券投资基金 | | | | 9 | Hillhouse G&L Holdings（HK）Limited | 4,357,832 | 0.73 | | 10 | STRONG LINK INTERNATIONAL LIMITED | 4,256,033 | 0.71 | 二、前十大无限售条件股东持股情况 | 序号 | 股东名称/姓名 | 持股数量（股） | 持股比例 （%） | | --- | --- | --- | --- | | 1 | 甘忠如 | 177,135,207 | 33.28 | | 2 | 北京旭特宏达科技有限公司 | 47,494,437 | 8.92 | | 3 | 香港中央结算有限公司 | ...

证券代码：603087 证券简称：甘李药业 公告编号：2024-070 甘李药业股份有限公司 关于以集中竞价交易方式回购股份方案的公告暨回购 报告书 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 回购股份金额：不低于人民币 15,000 万元（含）且不超过人民币 30,000 万 元（含） ● 回购股份价格：不超过 62.76 元/股（含本数），即不超过董事会通过回购股 份决议前 30 个交易日公司股票交易均价的 150% ● 回购股份方式：集中竞价交易方式 ● 相关风险提示： 1. 若在本次回购期限内，公司股票价格持续超出回购方案披露的价格上限， 进而导致本次回购方案无法顺利实施或者只能部分实施的风险； 2. 若发生公司生产经营、财务状况、外部客观情况发生重大变化等事项，可 能存在回购方案无法顺利实施或者根据规则变更或终止本次回购方案的风险； ● 回购股份资金来源：公司自有资金 ● 回购股份用途：用于实施员工持股计划或者股权激励 3. 本次回购股份将用于后续实施员工持股计划或股权激励，若公司未能按照 ...

Financial Performance - Revenue for the first half of 2024 reached 13.15 billion yuan, a year-on-year increase of 6.92%[2] - Net profit attributable to shareholders of the listed company was 2.99 billion yuan, a year-on-year increase of 122.80%[2] - Revenue for the first half of 2024 reached 1,314,892,845.25 yuan, a 6.92% increase compared to the same period last year[19] - Net profit attributable to shareholders of the listed company was 298,904,095.07 yuan, a significant increase of 122.80% year-over-year[19] - Operating income for the reporting period was 1.315 billion yuan, an increase of 6.92% year-on-year[22] - Net profit attributable to shareholders of the listed company increased significantly to 299 million yuan, driven by gains from changes in the fair value of financial assets and investment income[22] - The company achieved a revenue of 1,314.89 million yuan in the first half of 2024, a year-on-year increase of 6.92%, with domestic sales revenue reaching 1,188.33 million yuan, up 10.70% year-on-year[45] - The company's net profit attributable to shareholders was 298.90 million yuan in the first half of 2024, a significant year-on-year increase of 122.80%[45] - Total revenue for the first half of 2024 reached 1,314,892,845.25 RMB, a 6.9% increase compared to 1,229,765,113.65 RMB in the same period of 2023[161] - Net profit attributable to the parent company's shareholders in H1 2024 was 298,904,095.07 RMB, a 122.8% increase from 134,155,242.69 RMB in H1 2023[161] - Basic earnings per share (EPS) for H1 2024 was 0.51 RMB, up 112.5% from 0.24 RMB in H1 2023[162] R&D and Innovation - R&D investment in the first half of 2024 was 2.77 billion yuan, accounting for 21.05% of revenue[2] - The company's GLP-1 receptor agonist GZR18 showed a 17.29% weight reduction in Phase IIb clinical trials[2] - The company's GZR101 injection, a novel premixed dual insulin formulation, is under development for the treatment of diabetes[11] - GZR18 injection, a once-weekly GLP-1RA, has been approved for clinical trials targeting type 2 diabetes and obesity/overweight[12] - The company is developing GZR4 injection, a once-weekly ultra-long-acting insulin formulation for diabetes treatment[12] - GLR1023 injection, a biosimilar targeting IL-17A, is in development for the treatment of moderate to severe plaque psoriasis[12] - The company's GZR18 tablet, an oral peptide formulation using novel absorption technology, is under development for type 2 diabetes[12] - The company is developing GZR18, GZR4, and GZR101 injections for diabetes treatment, aiming to enrich patient options and increase market share[34] - The company is researching a GLP-1RA weekly formulation for overweight/obesity, potentially enabling bi-monthly dosing and creating new profit growth opportunities[34] - The company's product pipeline includes research in eukaryotic and prokaryotic protein engineering, oncology, cardiovascular, and metabolic diseases[34] - The company's GZR18 injection for type 2 diabetes and obesity/overweight weight management entered Ib/IIa phase clinical trials in 8 months and II phase in 12 months, demonstrating high efficiency in project advancement[37] - The company's GZR101, GZR4, and GZR18 injections, as well as GZR18 tablets, are all in clinical trial stages, with GLR1023 injection accelerating towards phase I clinical trials[37] - The company's insulin products, including glargine, lispro, and aspart insulin injections, have received EMA approval for commercialization in the EU, marking the first time a domestic insulin analog has passed EMA GMP inspection[37] - The company's glargine, lispro, and aspart insulin injections have been accepted by the FDA for review in the US, with preliminary feedback received and ongoing improvements being made[37] - The company's GZR18 injection, a long-acting GLP-1RA, completed Phase I clinical trials in the US in March 2022[43] - GZR18 injection showed an average weight loss of 17.8% (QW) and 12.8% (Q2W) in Chinese obese subjects over 35 weeks, compared to a 0.7% weight gain in the placebo group[46] - GZR18 tablet completed the first dosing in a Phase I clinical trial for type 2 diabetes in April 2024, aiming to improve bioavailability and patient compliance[47] - GZR4 injection, a fourth-generation insulin analog, demonstrated 2-3 times better glucose-lowering effects compared to Icodec in preclinical studies[47] - GZR101 injection, a fourth-generation premixed dual insulin formulation, completed the first dosing in a head-to-head Phase II trial against Degludec/Aspart in December 2023[47] - GZR101, a dual insulin formulation, has completed two Phase I clinical studies and entered Phase II globally, showing potential for 72-hour glucose control with no significant peak after 24 hours at steady state[48] - GLR1023, a biosimilar of Secukinumab, received clinical trial approval in July 2023 and is expected to address the global psoriasis market, which has a prevalence of 2-3% and generated $4.98 billion in global sales in 2023[48] - Empagliflozin, an SGLT-2 inhibitor, had its market application accepted in July 2023, targeting a global market with $18.9 billion in sales in 2023 and projected growth to $2030[48] - Linagliptin, a DPP-4 inhibitor, had its market application accepted in May 2024, targeting a global market with $2.585 billion in sales in 2023 and a 22% growth in China[49] Market and Sales - The company secured 46.86 million units in the insulin procurement agreement, a 32.6% increase from the previous procurement[2] - The company's third-generation insulin analogs accounted for 30% of the total procurement volume for third-generation insulin[2] - The company completed high-quality product supply to countries with high insulin demand, promoting international market revenue growth[2] - The company's production facilities passed the EU GMP inspection, marking a significant step in internationalization[2] - Domestic preparation sales revenue increased by 10.36% to 1.147 billion yuan[22] - The company sold securities investments worth 644 million yuan, resulting in a total gain of 141 million yuan from fair value changes and disposal[22] - The fair value of the company's remaining securities investments at the end of the reporting period was 261 million yuan[22] - The company's products cover long-acting, rapid-acting, and premixed insulin functional segments, with a focus on diabetes diagnosis and treatment[26] - The national centralized procurement demand for third-generation insulin in 2024 is 168 million units, accounting for 70% of the total demand, a 36% increase compared to the previous procurement[30] - Second-generation insulin accounts for 30% of the total demand in 2024, a 12% decrease compared to the previous procurement[30] - The company's main products, including Glargine Insulin Injection and Aspart Insulin Injection, were selected as Category A in the national insulin procurement, with prices of 65.30 RMB and 25.90 RMB respectively[31] - The company secured a procurement volume of 3.534 million units in the 2022 insulin centralized procurement, gaining access to nearly 10,000 new medical institutions and capturing a significant share from foreign competitors[33] - In the 2024 insulin follow-up procurement, the company obtained a first-year agreement volume of 4.686 million units, a 32.6% increase from the previous procurement, with its third-generation insulin products accounting for 37% of the total third-generation insulin allocation[34] - The company's third-generation insulin procurement demand in the 2024 follow-up procurement reached 1.68 billion units, representing 70% of the total demand, a 36% increase from the first procurement, while second-generation insulin demand decreased by 18%[33] - The company expanded its grassroots market team by recruiting nearly 1,000 medical representatives to enhance terminal market coverage and provide better academic services[33] - Domestic insulin sales are steadily increasing due to the acceleration of third-generation insulin replacing second-generation and domestic products replacing imports, driven by the national centralized procurement policy[35] - The company has established a robust supply chain system, ensuring continuous and timely product supply, and has gained market recognition through excellent quality control processes[35] - The company successfully secured bids for six insulin products in the national insulin procurement, gaining higher agreement volumes and entering nearly 2,000 new medical institutions[45] - The company passed the EMA pre-approval GMP inspection in May 2024, showcasing its potential as an industry leader[43] - The company's international strategy focuses on expanding its global team, investing in local markets, and promoting local distribution to diversify its international presence[42] - The company has established stable business relationships with international pharmaceutical companies and is accelerating the registration of medical devices in emerging markets[44] - The company's first FDA-approved product is the disposable insulin pen needle (Xiu Lin Needle®)[43] - The global GLP-1RA market is expected to reach $155.6 billion by 2030, with significant growth potential in China[46] - GZR18 injection is positioned to become the world's first GLP-1RA bi-weekly formulation, with no similar products currently on the market[46] - The company has a robust commercialization strategy with a 2,000+ member academic promotion team and strong brand presence in the diabetes treatment market[47] - The company has sufficient land and facility reserves to meet future supply demands for both domestic and global markets[47] - The company's pre-mixed insulin products, Su Xiulin® 25 and Rui Xiulin® 30, have seen rapid growth due to China's centralized procurement policy, accelerating the replacement of second-generation insulin with third-generation insulin[48] - The company's insulin procurement demand for 2024 increased by 151% to 41.77 million units, with third-generation insulin accounting for 24% of the total demand, up 10 percentage points from the previous procurement cycle[50] - The company's meal-time and pre-mixed insulin products saw growth rates of 381% and 564%, respectively, in the 2024 insulin procurement cycle[50] - The price line for Class A products in the insulin market shows consistency between second-generation insulin and third-generation meal-time and premixed insulin analogs, with prices at 25.93 yuan per unit[51] - The national insulin procurement results for 2024 show that Novo Nordisk secured a significant portion of the market with 2,103.11 million units of meal-time insulin analogs at 35.55 yuan per unit[52] - Gan & Lee Pharmaceuticals achieved a substantial procurement volume of 1,701.56 million units for basal insulin analogs at 65.30 yuan per unit[53] - The total procurement demand for premixed insulin analogs in 2024 reached 7,294.65 million units, with Novo Nordisk leading with 3,458.28 million units at 35.55 yuan per unit[54] - Tonghua Dongbao secured a procurement volume of 639.49 million units for meal-time human insulin at 25.93 yuan per unit[55] - The total procurement demand for basal human insulin in 2024 was 119.75 million units, with Tonghua Dongbao accounting for 44.27 million units at 25.93 yuan per unit[56] - The company's first-year procurement demand for this round of centralized procurement is 41.77 million units, an increase of 25.13 million units compared to the previous round, with a growth rate of 151%[62] - The company's procurement agreement volume for this round of centralized procurement is 46.86 million units (base volume of 36.19 million units and allocated volume of 10.67 million units), an increase of 11.52 million units compared to the previous round, with a growth rate of 32.6%[64] - The company's first-year procurement demand for basal insulin analogs increased by 4.25 million units compared to the previous round, the highest growth among all products[57] - The company's first-year procurement demand for mealtime and premixed insulin analogs increased by 381% and 564%, respectively, compared to the previous round[59] - The company's market coverage has expanded to 37,000 medical institutions by the end of 2023, with an additional 2,000 new medical institutions added in this round of centralized procurement[65] - The company's third-generation insulin analogs accounted for 30% of the total third-generation insulin agreement volume, with a base volume of 34.38 million units and an allocated volume of 9.17 million units[64] - The total first-year procurement demand for this round of centralized procurement is 242 million units, an increase of 28 million units compared to the previous round, with a growth rate of 13%[60] - The price range for third-generation basal insulin analogs narrowed from a previous gap of 30.49 yuan to 13.78 yuan, promoting market competition and accessibility[57] - The company's third-generation insulin analogs accounted for 70% of the total first-year procurement demand, up from 58% in the previous round[61] - The company's third-generation basal insulin analogs saw the highest growth in first-year procurement demand, increasing by 19.75 million units compared to the previous round[61] - International sales revenue increased by 15.90% year-over-year, with optimized product structure and a breakthrough in the export volume of Aspart 30 Insulin Injection[68] - The company successfully entered the Latin American market as a MAH in Bolivia and Mexico, and launched Aspart 30 Insulin Injection in Bangladesh, marking significant progress in overseas localization[67] - The company passed the EMA pre-approval GMP inspection in May 2024, becoming the first domestic insulin analog injection to meet EU GMP standards, enabling commercial production of insulin products in the EU[68] - The company's three innovative drugs, GZR18, GZR4, and GZR101, showcased breakthrough data at the 84th ADA Scientific Sessions, enhancing global academic attention and market competitiveness[68] - The company accelerated the construction of the Linyi production base in Shandong, which includes biopharmaceutical, chemical drug, and medical device facilities, to meet growing market demand and expand global commercialization[69] - The company strengthened supply chain resilience through improved information management, supplier collaboration, and cost optimization, ensuring stable product supply and competitive pricing[71] - The company completed the submission for production of Lispro Insulin Injection and Protamine Zinc Recombinant Lispro Insulin Mixed Injection (25R) at the Shandong facility, with feedback received from the regulatory authority[69] - The company emphasized quality management, passing the EMA GMP inspection and optimizing quality systems to ensure compliance with international standards and enhance product safety[72] Cash Flow and Financial Position - Net cash flow from operating activities improved to 66,235,604.55 yuan, compared to a negative cash flow of -58,165,721.17 yuan in the same period last year[21] - Total assets as of the end of the reporting period were 11,952,557,407.70 yuan, a 2.03% increase from the end of the previous year[21] - The company's total equity attributable to shareholders of the listed company increased by 2.18% to 10,977,088,892.82 yuan compared to the end of the previous year[21] - Basic earnings per share increased by 112.50% to 0.51 yuan per share compared to the same period last year[22] - Diluted earnings per share also increased by 112.50% to 0.51 yuan per share compared to the same period last year[22] - Non-recurring gains and losses amounted to 171.997 million yuan, primarily from gains on financial assets and government subsidies[23] - Total liabilities increased by 19.9% to 688,718,956.65 RMB in H1 2024 compared to 574,335,901.27 RMB in H1 2023[160] - Total equity attributable to the parent company's shareholders grew by 2.6% to 11,930,707,803.72 RMB in H1 2024 from 11,627,383,916.05 RMB in H1 2023[160] - R&D expenses in H1 2024 were 266,476,949.60 RMB, a 1.7% increase from 261,962,985.39 RMB in H1 2023[161] - Sales expenses rose by 5.5% to 490,979,157.99 RMB in H1 2024 compared to 465,243,177.81 RMB in H1 2023[161] - The company's financial income improved significantly, with financial expenses decreasing to -41,637,912.64 RMB in H1 2024 from -54,143,382.04 RMB in H1 2023[161] - Fair value gains surged to 154,127,142.24 RMB in H1 2024, a 1456.5% increase from 9,902,075.97 RMB in H1 2023[161] - The company's total assets increased by 3.4% to 12,619,426,760.37 RMB in H1 2024 from 12,201,719,817.32 RMB in H1 2023[160] - Operating cash flow increased to RMB 66.24 million in H1 2024, compared to a negative RMB 58.17 million in H1 2023[164] - Sales revenue from goods and services reached RMB 1.33 billion in H1 2024, up from RMB 1.16 billion in H1 2023[164] - Investment cash inflow totaled RMB 4.65 billion in H1 2024, a significant increase from RMB 2.79 billion in H1 2023[164] - Net cash outflow from investment activities was RMB 198.23 million in H1 2024, compared to a net inflow of RMB 12.00 million in H1 2023[164] - Cash and cash equivalents decreased by

证券代码：603087 证券简称：甘李药业 公告编号：2024-067 经中国证券监督管理委员会以"证监许可[2020]1075 号"文《关于核准甘 李药业股份有限公司首次公开发行股票的批复》核准，公司向社会公开发行人民 币普通股 40,200,000 股（A 股），每股面值人民币 1 元，发行价格为人民币 63.32 元/股，募集资金总额为人民币 2,545,464,000.00 元。扣减发行上市费用人民币 104,329,536.23 元（由于本公司对外销售自产的胰岛素产品按 3%的简易征收率 缴纳增值税，不予抵扣进项税，上述发行费用包含增值税金）后，本公司此次发 行 A 股募集资金净额计人民币 2,441,134,463.77 元。 上述募集资金于 2020 年 6 月 22 日全部到位，已经安永华明会计师事务所 （特殊普通合伙）审验，并出具了安永华明（2020）验字第 61234813_A01 号验 资报告。 截至 2024 年 6 月 30 日，公司对募集资金项目累计投入 2,080,202,894.36 元，其中，以前年度使用募集资金 2,080,202,894.36 元，本年度使用 0.00 元 ...

一、监事会会议召开情况 甘李药业股份有限公司（"公司"）第四届监事会第二十一次会议于 2024 年 8 月 16 日以电子邮件方式发出会议通知和会议材料，2024 年 8 月 27 日在公 司五层会议室以现场会议的形式召开。本次会议由监事会主席张涛先生主持。应 出席监事 3 名，实际出席监事 3 名。本次会议的召开符合《公司法》和《公司章 程》的有关规定，会议决议合法有效。 二、监事会会议审议情况 经与会监事审议表决，一致通过如下议案： 证券代码：603087 证券简称：甘李药业 公告编号：2024-066 甘李药业股份有限公司 第四届监事会第二十一次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 表决结果：3 票同意、0 票反对、0 票弃权。 （二）审议通过了《关于公司 2024 年半年度募集资金存放及实际使用情况 专项报告的议案》 同意《甘李药业股份有限公司 2024 年半年度募集资金存放及实际使用情况 专项报告》。 具体内容详见公司于同日在上海证券交易所网站披露的《甘李药业股份有限 公司 2024 年半年度 ...